Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T18:22:53.948Z.
Calculation as of: 2026-10-06T18:22:53.948Z.
Quote observation: 2026-10-06T18:15:57.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5fded3d3484fa1cf7e618a907758d95a7a48bcc7542cb4bc7c8f037a45079178
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$1.48M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.81M
Price/FCF Ratio
N/A
TTM Avg
81.45
3Y Avg
81.45
5Y Avg
81.45
Market Cap
$1.83M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Silo Pharma, Inc. (SILO) | $1.63M | N/A | N/A | N/A | N/A |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.48M | N/A | N/A | N/A | N/A |
| PMGC Holdings Inc. (ELAB)vs › | $1.48M | N/A | N/A | N/A | N/A |
| Curis, Inc. (CRIS)vs › | $1.46M | N/A | 58.11 | 58.11 | 58.11 |
| NEXGEL, Inc. (NXGL)vs › | $1.43M | N/A | N/A | N/A | N/A |
| Alaunos Therapeutics, Inc. (TCRT)vs › | $1.81M | N/A | 81.45 | 81.45 | 81.45 |
| INVO Fertility, Inc. (IVF)vs › | $1.43M | N/A | 8.14 | 8.14 | 8.14 |
| TransCode Therapeutics, Inc. (RNAZ)vs › | $1.83M | N/A | N/A | N/A | N/A |
| Tenon Medical, Inc. (TNON)vs › | $1.84M | N/A | N/A | N/A | N/A |
| Profusa, Inc. Common Stock (PFSA)vs › | $1.87M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
